DE69528168D1 - Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes - Google Patents

Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes

Info

Publication number
DE69528168D1
DE69528168D1 DE69528168T DE69528168T DE69528168D1 DE 69528168 D1 DE69528168 D1 DE 69528168D1 DE 69528168 T DE69528168 T DE 69528168T DE 69528168 T DE69528168 T DE 69528168T DE 69528168 D1 DE69528168 D1 DE 69528168D1
Authority
DE
Germany
Prior art keywords
diabetes
igf
prevention
subject
high risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69528168T
Other languages
English (en)
Other versions
DE69528168T2 (de
Inventor
Charles Thivolet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69528168D1 publication Critical patent/DE69528168D1/de
Application granted granted Critical
Publication of DE69528168T2 publication Critical patent/DE69528168T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69528168T 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes Expired - Fee Related DE69528168T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I
PCT/SE1995/000776 WO1996001124A1 (en) 1994-07-04 1995-06-22 Use of igf-i or analogues thereof in the prevention of diabetes

Publications (2)

Publication Number Publication Date
DE69528168D1 true DE69528168D1 (de) 2002-10-17
DE69528168T2 DE69528168T2 (de) 2003-01-09

Family

ID=20394633

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528168T Expired - Fee Related DE69528168T2 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes

Country Status (10)

Country Link
US (2) US6342227B1 (de)
EP (1) EP0759776B1 (de)
JP (1) JPH10502367A (de)
AT (1) ATE223729T1 (de)
AU (1) AU689922B2 (de)
CA (1) CA2194403A1 (de)
DE (1) DE69528168T2 (de)
IL (1) IL114343A0 (de)
SE (1) SE9402370D0 (de)
WO (1) WO1996001124A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
CA2369451C (en) 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
EP1282437B1 (de) 2000-05-16 2008-03-19 Genentech, Inc. Behandlung von knorpelerkrankungen
HUP0500733A3 (en) 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2011004051A1 (es) 2009-07-10 2011-01-13 Universidad Autónoma De Barcelona Composiciones de terapia génica para prevenir y/o tratar enfermedades autoinmunes
US10799564B1 (en) * 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (de) 1983-04-25 2002-07-03 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1

Also Published As

Publication number Publication date
AU689922B2 (en) 1998-04-09
ATE223729T1 (de) 2002-09-15
JPH10502367A (ja) 1998-03-03
EP0759776A1 (de) 1997-03-05
IL114343A0 (en) 1995-10-31
WO1996001124A1 (en) 1996-01-18
DE69528168T2 (de) 2003-01-09
CA2194403A1 (en) 1996-01-18
AU2940795A (en) 1996-01-25
US20020132772A1 (en) 2002-09-19
SE9402370D0 (sv) 1994-07-04
US6342227B1 (en) 2002-01-29
EP0759776B1 (de) 2002-09-11

Similar Documents

Publication Publication Date Title
DE69528168T2 (de) Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
DE3566314D1 (en) Apparatus for saving a calculator status
BR6300196U (pt) Tenis, em especial chuteira, com uma primeira sola elastica
IT1187739B (it) Cella elettrochimica
JPS5388761A (en) Electronic watch with auxiliary battery
IT8519661A0 (it) Soluzione oftalmica ad azione antiinfiammatoria
IT8348747A0 (it) Derivati amminometil-benzenici eteroaril-sostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni farmaceutiche che li contengono
ATE65696T1 (de) Verwendung von defibrotid bei der behandlung von zustaenden akuter nierenschwaeche.
ATE207758T1 (de) Verwendung von igf-1
DE3381121D1 (de) Multiplexbare fluessigkristallzelle.
AU548677B2 (en) Peptides derived from glucagon
DK353484D0 (da) Arkhaandteringsarrangement til opdeling af en arkstroem i mindst to arkstroemme
DE3577151D1 (de) Fehlertolerante speichermatrix.
ES499902A0 (es) Perfeccionamiento en cilindros con compensacion de flexion especialmente para el tratamiento de una banda de genero.
IT1141184B (it) Elettrodo attivo,cella elettrochimica comprendente detto elettrodo e metodo di fabbricazione dell'elettrodo
IT8419681A0 (it) Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche.
IT1149034B (it) Cella elettrochimica con anodo gelificato
DK468885A (da) Middel til topisk behandling af betaendelsestilstande i huden
Woolfe Counselling in a world of crisis: towards a sociology of counselling.
JPS52114322A (en) Photographic lens
JPS5257731A (en) Light source for information reading element
JPS6474401A (en) Disk type thickness gauge
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.
IT1214708B (it) Impiego del dietilaminoetil-destrano (deae-d) come farmaco antidiabetico (diabete tipo i-ii-iii) e regolatore del metabolismo glucidico
JPS5429597A (en) Diapason type crystal oscillator

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8339 Ceased/non-payment of the annual fee